AOD-9604 vs Ipamorelin
Side-by-side comparison of AOD-9604, Ipamorelin — mechanism, dosing, half-life, side effects, and research status.
| Attribute | AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss | Ipamorelin Ipamorelin (Selective GHRP) Growth Hormone |
|---|---|---|
| Basics | ||
| Molecular type | hGH C-terminal Fragment | Growth Hormone Releasing Peptide (GHRP) |
| Amino acids | 16 | 5 |
| Molecular weight | 1,815.1 Da | 711.9 Da |
| Half-life | ~30 min | ~2 hours |
| Route(s) | Subcutaneous, Oral (research) | Subcutaneous, Intramuscular |
| Mechanism & Research | ||
| Primary mechanism | AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri… | Ipamorelin activates growth hormone secretagogue receptors (GHSR-1a) in the pituitary, triggering pulsatile GH release. Unlike first-generation GHRPs (GHRP-6, GHRP-2), ipamorelin's selectivity for GHSR-1a is high enough … |
| Research status | Research Compound | Research Compound |
| Evidence summary | AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si… | Ipamorelin was among the first highly selective GHRPs to enter research. Phase 1 trials confirmed its clean hormonal profile. It remains a reference GHRP in comparative studies and is widely used as the GHRP component in… |
| Protocol & Dosing | ||
| Typical dose | 300–500 mcg/day | 100–300 mcg per injection |
| Frequency | Once daily | 2–3x daily (or 1x at bedtime) |
| Duration | 8–12 weeks | 8–12 weeks on, 4 weeks off |
| Timing | Pre-workout or morning on empty stomach (for metabolic effects) | Fasted state or 2+ hours post-meal for maximum GH response; bedtime dosing utilises natural nocturnal GH pulse |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S2) | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | Semaglutide, Ipamorelin, Tesamorelin | CJC-1295, GHRP-2, Sermorelin, Tesamorelin |
| Full profile | Read full AOD-9604 profile → | Read full Ipamorelin profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.